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RESULTS: The two methods of measuring BNP (Biosite and Bayer) gave nearly identical
results. One hour following a bolus dose of Natrecor, the average concentrations of BNP
increased about three fold (<0.001). For example, in patients who received the 48 hour
infusion, the average baseline, 1 hour, 48 hour and 12 hour post infusion concentrations
of BNP (Biosite assay) were 1100, 3700, 1900 and 600 pg/mL respectively. The 12 hour
post infusion concentration of BNP was significantly lower (<0.05) than baseline for this
group. In contrast to the BNP results, proBNP concentrations did not increase following
Natrecor administration. For example, in the 48 hour infusion group, the average base-
line, 1 hour, 48 hour and 12 hour post infusion concentrations of proBNP were 9600,
9100, 4400 and 4400 pg/mL respectively. At the end of the infusion and 12 hours after
the infusion, the concentrations of proBNP were significantly (<0.001) lower than base-
line for this group. The proBNP results were not as easily interpreted for the groups that
received infusions < 48 hours.
CONCLUSION: Following the bolus dose, average BNP concentrations trended down
during the infusion, suggesting both drug clearance and turn-off of endogenous synthe-
sis. The decrease in proBNP likely reflects turn-off of endogenous synthesis. Thus both
BNP (endogenous and drug) and proBNP (endogenous secretion) levels can be used to
monitor the concentrations of these peptides in patients administered Natrecor.
1049-113 Prospective Study in Search of an Optimal B-Type 
Natriuretic Peptide Level to Screen Patients for Cardiac 
Dysfunction
Meenakshi A. Bhalla, Vikas Bhalla, Dunya Atisha, L. Katherine Morrison, Leda Felicio, 
Paul Clopton, Nancy Gardetto, Radmila Kazanegra, Albert Chiu, Alan S. Maisel, 
Veteran's Affairs Medical Center, San Deigo, CA, University of California, San Diego, CA
BACKGROUND: Although echocardiography is the gold standard test for the suspected
Left Ventricular dysfunction (LVD),the cost and availability, limits its use as a routine
screening tool. Determining an appropriate BNP level below that would preclude the
need for echocardiography would be valuable. We hypothesized that a fixed plasma BNP
level of 20pg/ml and simple clinical parameters would be an effective pre-echocardio-
graphic screening tool for LV dysfunction. METHODS: 202 VA subjects with symptoms
suggestive of heart disease (m:f 193:9, mean-age 65) were screened prior to echocar-
diography. Patients with known cardiac dysfunction were excluded. RESULTS: BNP lev-
els of 20pg/ml and above were 79% sensitive and 44% specific in screening for any
abnormality of ventricular function.The negative predictive value was 69%.When broken
down into categories of dysfunction, the cut point of 20pg/ml had a better negative pre-
dictive value for those with systolic dysfunction (96%), or systolic plus diastolic dysfunc-
tion (100%) if patients with diastolic dysfunction were excluded. The majority of patients
with falsely low BNP levels (<20pg/ml with positive echo findings) had mild diastolic dys-
function,with 3 patients exhibiting mild systolic dysfunction. CONCLUSION: BNP may be
useful screening tool for LVD in patients with history suggestive of heart disease and may
assist in forming a pre-test probability which could greatly assist in appropriateness of
patient referral and in optimization of drug therapy.
1049-114 Increasing Atrial Natriuretic Peptide Over Time 
Independently Predicts Higher Short-Term Mortality and 
Morbidity in Heart Failure
Raymond T. Yan, Rizwan Afzal, Robert S. McKelvie, McMaster University, Hamilton, ON, 
Canada
Background: Baseline measurements of various neurohormones (NH) have been
reported as useful prognostic markers in heart failure (HF). However, the prognostic val-
ues of changes in these different NH over time have not been examined.
Methods: We evaluated 768 subjects with symptomatic HF and left ventricular ejection
fraction <0.40 randomized to various combinations of candesartan, enalapril and meto-
prolol in RESOLVD. Changes (∆) (week 17 - baseline) in each measured NH were com-
pared between subjects with and without subsequent (week 17 to week 43) death or HF
hospitalization, and their independent prognostic significance were determined by Cox
regression analysis.
Results: All NH were abnormally elevated at baseline. Subjects who subsequently died
or required hospitalization for HF had significantly larger increases in atrial natriuretic
peptide (ANP) and smaller decreases in norepinephrine (NE). In Cox regression analy-
sis, every 2-fold increase in ANP over time independently predicted an increased risk of
subsequent death or HF hospitalization (Hazard ratio 1.53, 95% CI 0.93 to 3.63, p=0.07).
Changes in other NH conferred no incremental prognostic value. 
Conclusion: Increasing ANP over time independently predicted a trend towards higher 
short-term mortality and morbidity in chronic HF patients on neurohormonal therapies. 
Serial measurements for changes in ANP may help to identify higher risk HF patients and 
should be evaluated in further studies.
1049-115 The Value of B-Type Natriuretic Peptide and Cardiac 
Troponin I as Predictors of Sudden Death in Patients 
With Advanced Heart Failure
Mark M. Lensky, Tamara B. Horwich, Gregg C. Fonarow, University of California at Los 
Angeles Medical Center, Los Angeles, CA
Objectives: The study aimed to evaluate the potential role of BNP and cardiac troponin I
(TnI) as predictors of sudden death (SD) in patients with advanced heart failure (HF).
Background: Earlier studies have reported that BNP and TnI are predictive of mortality
in HF patients: their role in predicting SD in HF has not been well studied.
Methods: We analyzed 757 advanced HF patients followed in a comprehensive HF man-
agement program of which 303 had baseline BNP and 403 had TnI determined. The
patients were grouped into those with undetectable TnI < 0.04 ng/mL (n = 187) and
detectable TnI > 0.04 (n = 216) as well as those with BNP < 950 pg/mL (n= 226) and
BNP > 950 (n =77). The BNP cut point was selected based on ROC curves for SD.
Results: Of 110 deaths during 2 years of follow-up 42 (38%) were classified as SD.
Detectable TnI (OR 2.81, 95% CI 1.70-4.64) and BNP > 950 (OR 8.76, 95% CI 4.65-
19.50) predicated significantly increased risk of all-cause mortality. While BNP > 950 was
highly predictive of SD risk (OR 4.75, 95% CI 1.32-17.15), detectable TnI was only asso-
ciated with a non-significant trend (OR 1.72, 95% CI 0.78-3.79). On multivariate analysis,
BNP < 950 was a strong predictor of SD free survival; non-detectable TnI was not.
Conclusions: In a large cohort of patients with advanced HF of multiple etiologies, ele-
vated BNP, but not detectable TnI, is highly predictive of increased risk for SD. Prospec-
tive studies are needed to test if BNP can be used to guide prophylactic Implantable
Cardioverter Defibrillator device placement in HF.
1049-116 B-Type Natriuretic Peptide Does Not Correlate With 
Volume Overload or Left Ventricular Dysfunction in 
Patients With Multiple Comorbidities
Sukesh C. Burjonroppa, Mary Vooletich, Daniel J. Lenihan, University of Texas, MD 
Anderson Caner Center, Houston, TX
Background: B type Natriuretic peptide (BNP) has been shown to be an important
marker of left ventricular (LV) systolic dysfunction and volume overload (VOL) in patients
with symptomatic heart failure (HF).In addition, the level of BNP elevation in HF has cor-
related with prognosis. However marked elevation of BNP can be noted without VOL.
Thus, we hypothesized that these elevated BNP levels may reflect non-specific eleva-
tions due to co-morbid diseases rather than due to VOL alone.
Methods: Over a 6-month period, all patients admitted with BNP levels greater than
1000 pg/ml were identified. The demographics, co-morbidities including the presence of
sepsis, any clinical evidence of VOL (S3 gallop, bilateral basilar crackles, bilateral pedal
edema, jugular venous distension, pulmonary edema) and measurement of LV ejection
fraction (LVEF) within 48 hours of the BNP data were defined.
Comparison of BNP cut off of 20pg/ml vs Echocardiography as a screening tool in 
Cardiac Failure
Sensitivity Specificity Positive 
Predictive 
Value
Negative 
Predictive 
Value
Accuracy
All Unknown 
LVD
79%(69-86) 44%(35-54) 57%(48-65 69%(56-79 61%
Only Systolic 80%(50-98) 36%(30-44) 10%(6-16) 96%(87-99) 40%
Only Diastolic 75%(63-84) 38%(30-47) 40%(32-49) 73%(61-83) 51%
Systolic & 
Diastolic
100%(70-105) 35%(29-42) 8%(5-14) 100%(94-100) 39%
Subjects without 
Death or HF 
hospitalization
(Mean ± SD)
(N=598)
Subjects with 
Death or HF 
hospitalization
(Mean ± SD)
(N=87)
P–value
t-test
∆ ANP (pmol/ml) -21.5 ± 628.2 +293.7 ± 648.3 0.006
∆ NE (pg/ml) -48.5 ± 242.9 - 22.3 ± 232.5 0.04
∆ Brain natriuretic peptide (pmol/ml) - 5.3 ± 35.8 + 1.2 ± 52.0 0.15
∆ Endothelin (pg/ml) - 0.63 ± 3.63 - 0.36 ± 2.25 0.36
∆ Angiotensin (pg/ml) + 5.8 ± 30.2 + 13.5 ± 34.8 0.59
∆ Aldosterone (pg/ml) - 9.5 ± 102.2 - 14.7 ± 102.5 0.92
∆ Epinephrine (pg/ml) - 24.1 ± 92.4 - 26.7 ± 56.5 0.80
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Results: A total of 76 patients (61±15 years, 35 male/41 female) had a mean BNP (pg/
ml) of 2766± 1398 (SD) of whom 50 (66%) had LVEF >40 and only 17 (22%) had VOL.
All patients had a recent history of cancer- 34 (45%) had a hematological malignancy
and 42 (55%) had a solid tumor. 43 patients (57%) had evidence of sepsis. Of these 43
patients, 40 did not have VOL and 35 had LVEF>40. The BNP values, although all ele-
vated, were higher in VOL (3463±1439, n=17) versus NO VOL (2565±1332, n=59)
p<0.05. Similarly, BNP values were higher if LVEF<40 (3273±1474, n=26) versus
LVEF>40 (2502±1294, n=50), p<0.05 by ANOVA.
Conclusion: Markedly elevated BNP values obtained on cancer patients admitted with
multiple co-morbidities may not reliably indicate VOL or reflect LV dysfunction. In patients
with cancer and infectious complications, therapeutic decisions may need to be guided
more by clinical evidence as opposed to laboratory evidence of HF or VOL. It is possible
that other factors, such as IL-6 or other cytokines, may stimulate BNP release in the
absence of significant VOL or perhaps interfere with the standard assay giving errone-
ously high values.
1049-117 B-Type Natriuretic Peptide Is a Biochemical Predictor of 
Myocardial Contractile Reserve During Dobutamine 
Stress Echocardiogram
Ann Tong, Daniel Lenihan, Vivjay Divakaran, Jessica M. Tristan, Mona Nemer, Joseph 
Swafford, Gregory Geisler, Mary Vooletich, Beverly Handy, Jean-Bernard Durand, 
University of Texas, M.D. Anderson Cancer Center, Houston, TX
Dobutamine Stress Echocardiography (DSE) is used to assess myocardial contractile
reserve (CR) in ischemic and dilated cardiomyopathy (CMP). A higher CR is associated
with improved prognosis and LVEF with optimal therapy. No data is available in patients
with chemotherapy-induced CMP. Technical limitations due to imaging may reduce the
diagnostic ability of DSE. Brain Natriuretic Peptide (BNP), a neurohormone secreted
from the ventricle in response to volume overload, may provide additional predictive
power to DSE.
We hypothesized that BNP can be used as a biochemical marker for CR and may
improve diagnostic capability of DSE. BNP levels were obtained at baseline and peak
infusion during DSE in 42 patients (23 men, 19 women) with LVEF < 45%. Baseline
demographics: mean age 61±14 yrs, prior chemotherapy 67%, ischemic heart disease
34%, hypertension 36%, diabetes 12%, and NYHA class 2.3±0.9. Patients were catego-
rized based on response of BNP during DSE: Group 1 (n=22, BNP falls) and Group 2
(n=20, BNP rises). See Table 1. With linear regression analysis, there was a significant
inverse correlation between changes in BNP and LVEF pre and post DSE (r=0.6,
p<0.001). 
BNP can identify CR in conjunction with DSE and may be helpful in technically difficult 
studies. A decrease in BNP after DSE is strongly correlated with the presence of CR as 
shown by an increase in LVEF. In chemotherapy-induced CMP, a condition generally con-
sidered irreversible, BNP in conjunction with DSE may predict improvement of cardiac 
function.
1049-118 N-Terminal Pro-Brain Natriuretic Peptide and Urinary 
Albumin Excretion Is Independent Predictors of All 
Cause Mortality in the General Population
Caroline Kistorp, Ilan Raymond, Frants Pedersen, Jens Faber, Per Hildebrandt, 
Frederiksberg University Hospital, Frederiksberg, Denmark
Background: N-terminal proBNP (NT-proBNP) and urinary albumin excretion is known
important risk factors for mortality in patients with chronic heart failure (CHF) and diabe-
tes mellitus, respectively. It is unclear whether these unconventional risk factors are inde-
pendent predictors of all cause mortality in the general population.
Methods: A total of 658 subjects (age 51-91 years), were consecutively recruited from 4
general practitioners in the Frederiksberg municipality. All subjects underwent echocar-
diography, measuring left ventricular ejection fraction (LVEF), and plasma NT-proBNP
and urinary albumin/creatinine ratio (A/C ratio) were measured at baseline. Mean follow-
up time was 48 months. Using multivariate Cox proportional hazard models, the prognos-
tic value of the upper quartile of plasma NT-proBNP and urinary A/C ratio was evaluated
in two models: Model 1 (total population). Model 2 (after exclusion of patients with known
heart failure or LVEF <=50 %, as well as, diabetes by history or HbA1c >= 6.1 %).
Results: During follow-up there were 55 (8.4 %) deaths from any cause in the total pop-
ulation (n = 658). Plasma levels of NT-proBNP and urinary A/C ratio in the upper quartile,
was associated with increased risk for total mortality. For NT-proBNP, hazard ratio (HR)
was 3.6 (95% CI: 1.6-6.7, p < 0.0001); for urinary A/C ratio, HR was 2.6 (95% CI: 1.4-4.9,
p=0.002). In model 2 (n = 495) mortality rates were 5.3 %. For NT-proBNP, HR was 2.8
(95% CI: 1.3-6.2, p=0.009); for urinary A/C ratio, HR was 5.1 (95% CI: 1.8-13.9,
p=0.0019), after adjustment for age, gender, LVEF and established risk factors in both
models. Median urinary A/C ratio (mg/g) and plasma NT-proBNP (pmol/l) levels in sub-
jects who died was 20 mg/g (4-274), and 94.0 pmol/l (18.3-1633.2), compared with 6 mg/
g (3-66) and 30.1 pmol/l (5.2-202.6) in survivors, p < 0.0001 for both.
Conclusion: Plasma NT-proBNP and urinary albumin are independent risk factors for
total mortality in the general population. Even when excluding patients with conditions
associated with increased plasma NT-proBNP and urinary albumin excretion, both
unconventional risk factors remained strong prognostic predictors.
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1050-120 Echocardiographic and Angiographic Correlations in 
Cardiogenic Shock
M. Joshua Berkowitz, Shannon Harkness, Judith Hochman, Michael Picard, Timothy 
Sanborn, Norma Keller, James Slater, New York University Hospital, New York, NY
Objectives: We investigated the correlation between echocardiographic and angio-
graphic core lab data in patients with cardiogenic shock (CS) complicating AMI.
Background: In patients with CS complicating AMI, both echocardiographic and angio-
graphic findings are used to aid diagnosis, determine prognosis, and guide management.
The purpose of this study of the SHOCK trial is to identify relationships between the
angiographic and echocardiographic features of patients with CS. Such an analysis may
provide insights into the etiology and treatment of CS.
Methods/Results: Of 302 randomized patients, a pre-revascularization echocardiogram
and angiogram was available in 119 patients. The correlations between almost all echo
and angiographic parameters collected within 4 hours and greater than 4 hours of each
other were similar. Although the median ejection fraction (EF) derived by echo and LV
angiogram was identical, 29.5%, this significant positive correlation was weak (R2=.209,
p=.019) as was the significant negative correlation between EF and angiographic jeop-
ardy scores (R2=.145, p=.001). Although the presence of left main obstruction (>50%
stenosis) was associated with lower LVEF (26% vs.31%, p= .031) there was only a trend
for decreasing EF with number of diseased vessels. Patients with a higher number of dis-
eased vessels had worse MR by echo (p=.005). There was a significant but weak associ-
ation between LV gram MR grade and echo MR severity (R2=.162, p=.015), but there
was no association between culprit vessel and degree of MR. Patients with TIMI grade 0/
1 were more likely to have impaired LV function (p=.029). Collateral flow to the culprit
vessel was not associated with improved EF. There was a trend towards an increased
incidence of LV thrombus in LAD culprit vessels (p=.060).
Conclusions: Higher angiographic jeopardy scores and low TIMI flow scores are associ-
ated with worse LV function but collateral flow to the culprit vessel is not associated with
improved EF by echo. Worse CAD is associated with more severe MR. Both echo and
angiography are valuable and result in similar estimated EF's in a large cohort however
there is wide variation between the techniques in individual patients.
1050-121 Echocardiographic, Electrophysiological, Histological, 
and Serological Recovery During Left Ventricular Assist 
Device Support
Steve Xydas, Jason Cohen, Yoshifumi Naka, Donna M. Mancini, Marco DiTullio, Amanda 
D. Arnold, Chuck Ng, Mehmet C. Oz, Simon Maybaum, Columbia University College of 
Physicians and Surgeons, New York, NY
Background: Mechanical unloading during left ventricular assist device (LVAD) support
may lead to cardiac recovery, however, clinical markers of recovery have yet to be identi-
fied. We sought to define the echocardiographic (echo), EKG, serological and histologi-
cal changes during device support.
Methods: LVAD patients underwent monthly evaluation, including echo, EKG and serum
BNP measurement. Paired myocardial tissue samples from implant and explant were
analyzed.
Results: 32 LVAD patients were prospectively followed. Duration of heart failure was
47.3 ± 99.1 months and duration of support was 103.2 ± 85 days. Left ventricular ejection
fraction (LVEF) and end-diastolic diameter significantly improved at 30 days as compared
to pre-LVAD, with no further improvement with longer periods of support. At 30 and 60
days, QTc and QRS were significantly decreased from pre-LVAD. There was a marked
reduction in BNP, myocyte size, and collagen deposition during LVAD support. In screen-
ing for markers of recovery, the decrease in QTc correlated with LVEF at 30 days (R = -
0.993, p < .01). Interestingly, changes in QRS correlated with the drop in myocardial col-
lagen deposition (R = -0.976, p < .01). No study patients had sufficient recovery for
device explantation.
Conclusions: We demonstrate echo, EKG, histologic, and serological improvement dur-
ing LVAD support. Recovery is evident at 30 days and is sustained through 90 days of
support. Further prospective data collection may yield important markers of recovery.
Table 1
Change in 
BNP(pg/ml)
Pre-DSE 
LVEF(%)
Post- 
DSE  
LVEF (%)
Change in 
LVEF(%)*
Group 1 (fall in BNP) -110±90 35±9 49±11 14±5
Group 2 (rise in BNP) 68±84 33±9 38±12 4±8
all data is mean ± SD
* change in LVEF inversely correlates with change in BNP, <0.001
